Abstract Number: 0451 • ACR Convergence 2023
Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor for the treatment of moderate to severe active RA. A previous pooled analysis reported…Abstract Number: 1323 • ACR Convergence 2023
Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1
Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate…Abstract Number: 1325 • ACR Convergence 2023
Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor, approved for the treatment of moderate to severe active rheumatoid arthritis (RA). In previous…Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…Abstract Number: 1343 • ACR Convergence 2023
Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor for the treatment of RA. Data from the ORAL Surveillance post-marketing study (NCT02092467) suggest…Abstract Number: 2143 • ACR Convergence 2023
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study
Background/Purpose: In the treatment of RA, JAK inhibitors are a valuable option to meet remission or low disease activity (LDA) treatment targets following an inadequate…Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…Abstract Number: 2162 • ACR Convergence 2023
Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure
Background/Purpose: DARWIN 3 (NCT02065700) is a long-term extension (LTE) study assessing the safety and efficacy of filgotinib (FIL) in patients with rheumatoid arthritis (RA) and…Abstract Number: 0273 • ACR Convergence 2022
An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderately to Severely Active RA
Background/Purpose: Filgotinib (FIL) is a second-generation oral Janus kinase 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment of RA.1,2 Over a…Abstract Number: 0275 • ACR Convergence 2022
Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Background/Purpose: The safety profile of filgotinib (FIL), a second-generation oral Janus kinase (JAK) 1 preferential inhibitor approved in Europe, Japan, and the UK for treatment…Abstract Number: 0276 • ACR Convergence 2022
Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor, approved in Europe for the treatment of RA and ulcerative colitis. A phase 4 European…Abstract Number: 0277 • ACR Convergence 2022
Malignancy Events in the Filgotinib Rheumatoid Arthritis and Ulcerative Colitis Clinical Development Programs
Background/Purpose: Filgotinib (FIL) is a preferential oral Janus kinase (JAK) 1 inhibitor, approved for the treatment of RA and ulcerative colitis (UC) in Europe, the…Abstract Number: 0278 • ACR Convergence 2022
The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA
Background/Purpose: Reporting of treatment-emergent adverse events (TEAEs) in RA clinical trials can be summarized as exposure-adjusted incidence rates (EAIRs) or exposure-adjusted event rates (EAERs). Censored…Abstract Number: 0279 • ACR Convergence 2022
Effect of Filgotinib on Body Weight and BMI and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in RA
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor approved for the treatment (tx) of moderate to severe RA. Weight gain has been…Abstract Number: 0280 • ACR Convergence 2022
Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
Background/Purpose: Filgotinib (FIL) is a Janus kinase (JAK) 1 preferential inhibitor, approved for treatment of moderate to severe active RA in Europe, the UK, and…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »